<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04052594</url>
  </required_header>
  <id_info>
    <org_study_id>17394</org_study_id>
    <secondary_id>J1T-MC-GZEA</secondary_id>
    <nct_id>NCT04052594</nct_id>
  </id_info>
  <brief_title>A Study of LY3475766 in Healthy Participants</brief_title>
  <official_title>A Randomized, Double-Blind, Single Dose, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3475766</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and tolerability of LY3475766 when given to participants&#xD;
      with high levels of blood fat called triglycerides. It will also investigate how the body&#xD;
      processes the study drug and the effect of the study drug on the body. Information about any&#xD;
      side effects will be documented. This study will last up to 16 weeks for each participant.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 3, 2019</start_date>
  <completion_date type="Actual">March 31, 2021</completion_date>
  <primary_completion_date type="Actual">March 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline up to Day 85</time_frame>
    <description>A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3475766</measure>
    <time_frame>Predose up to Day 85</time_frame>
    <description>PK: AUC of LY3475766</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Maximum Observed Drug Concentration (Cmax) of LY3475766</measure>
    <time_frame>Predose up to Day 85</time_frame>
    <description>PK: Cmax of LY3475766</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Time to Maximum Observed Drug Concentration (Tmax) of LY3475766</measure>
    <time_frame>Predose up to Day 85</time_frame>
    <description>PK: Tmax of LY3475766</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD): Percent Change from Baseline in Triglycerides (TG)</measure>
    <time_frame>Baseline, Day 85</time_frame>
    <description>PD: Percent Change from Baseline in TG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD: Percent Change from Baseline in Low-Density Lipoprotein Cholesterol (LDL-C)</measure>
    <time_frame>Baseline, Day 85</time_frame>
    <description>PD: Percent Change from Baseline in LDL-C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD: Percent Change from Baseline in Apolipoprotein B (ApoB)</measure>
    <time_frame>Baseline, Day 85</time_frame>
    <description>PD: Percent Change from Baseline in ApoB</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>LY3475766 - IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3475766 administered intravenously (IV) to participants with dyslipidemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - IV</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered IV to participants with dyslipidemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3475766 - SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3475766 administered subcutaneously (SC) to participants with dyslipidemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - SC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered SC to participants with dyslipidemia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3475766 - IV</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>LY3475766 - IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3475766 - SC</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>LY3475766 - SC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - IV</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Placebo - IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - SC</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo - SC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are overtly healthy males or females, apart from dyslipidemia&#xD;
&#xD;
          -  Male participants must agree to adhere to contraception restrictions&#xD;
&#xD;
          -  Female participants must be of nonchildbearing potential and include those who are&#xD;
             infertile due to surgical sterilization or those who are postmenopausal&#xD;
&#xD;
          -  Have a body mass index (BMI) &gt;18.5 and &lt;40 kilograms per meter squared (kg/m²)&#xD;
&#xD;
          -  Have clinical laboratory test results within normal reference range, or acceptable&#xD;
             deviations per investigator discretion&#xD;
&#xD;
          -  Have a fasting triglyceride (TG) level that is 135 to 499 milligrams per deciliter&#xD;
             (mg/dL), inclusive, at both screening and Day -1&#xD;
&#xD;
          -  Have a fasting low density lipoprotein cholesterol (LDL-C) level greater than or equal&#xD;
             to (≥) 70 mg/dL, inclusive, at screening and Day -1&#xD;
&#xD;
          -  Have had a stable body weight for the 3 months prior to randomization (&lt;5% body weight&#xD;
             change)&#xD;
&#xD;
          -  Have not modified diet or adopted any nutritional lifestyle modification within 3&#xD;
             months prior to randomization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Are taking or have started taking Proprotein convertase subtilisin/kexin type 9&#xD;
             (PCSK9) inhibitors within 3 months prior to randomization; or statins, fibrates, or&#xD;
             niacin ≤1000 mg/day within 8 weeks prior to randomization; or niacin &gt;1000 milligrams&#xD;
             per day (mg/day) within 16 weeks prior to randomization; or any other lipid-lowering&#xD;
             agents within 1 month prior to randomization&#xD;
&#xD;
          -  Are taking or have started taking a beta-blocker, antiarrhythmic, non-dihydropyridine&#xD;
             calcium channel blocker, ivabradine, or any other heart rate lowering agent within 1&#xD;
             month or 5 half-lives prior to randomization, whichever is longer&#xD;
&#xD;
          -  Have a diagnosis of diabetes mellitus (type 1 diabetes mellitus or type 2 diabetes&#xD;
             mellitus) or have 1 of the following at screening: fasting plasma glucose&#xD;
             concentration ≥126 mg/dL (7.0 millimoles per liter [mmol/L]) OR a glycated hemoglobin&#xD;
             level ≥6.5% (48 millimoles per mole [mmol/mol])&#xD;
&#xD;
          -  Have previously completed or withdrawn from this study or any other study&#xD;
             investigating LY3475766, and have previously received the investigational product&#xD;
&#xD;
          -  Have known allergies to LY3475766, related compounds, or any components of the&#xD;
             formulation, or history of significant atopy&#xD;
&#xD;
          -  Have a seated heart rate ≤50 beats per minute&#xD;
&#xD;
          -  Have clinically significant abnormal electrocardiogram (ECG) results constituting a&#xD;
             risk while taking the investigational product, as determined by the investigator&#xD;
&#xD;
          -  Have an abnormal blood pressure (BP) as determined by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>WCCT Global</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covance Clinical Research Inc</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covance Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covance Clinical Research Inc</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 15, 2021</verification_date>
  <study_first_submitted>August 8, 2019</study_first_submitted>
  <study_first_submitted_qc>August 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2019</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

